[1] Stavraka C,Rush H,Ross P. Combined hepatocellular cholangiocarcinoma (cHCC-CC): an update of genetics, molecular biology, and therapeutic interventions. J Hepatocell Carcinoma,2019,6:11-21.
[2] Zhao Q,Yu W,Lu X, et al. Combined hepatocellular and cholangiocarcinoma originating from the same clone: a pathomolecular evidence-based study. Chin J Cancer,2016,35:82.
[3] Kim T,Kim H,Joo I, et al. Combined Hepatocellular-Cholangiocarcinoma: Changes in the 2019 World Health Organization Histological Classification System and Potential Impact on Imaging-Based Diagnosis. Korean J Radiol,2020,21:1115-1125.
[4] Schizas D,Mastoraki A,Routsi E, et al. Combined hepatocellular-cholangiocarcinoma: An update on epidemiology, classification, diagnosis and management. Hepatobiliary Pancreat Dis Int,2020,19:515-523.
[5] Zhang H,Yu X,Xu J, et al. Combined hepatocellular-cholangiocarcinoma: An analysis of clinicopathological characteristics after surgery. Medicine,2019,98:e17102.
[6] Wakizaka K,Yokoo H,Kamiyama T, et al. Clinical and pathological features of combined hepatocellular-cholangiocarcinoma compared with other liver cancers. J Gastroenterol Hepatol,2019,34:1074-1080.
[7] Sagrini E,Iavarone M,Stefanini F, et al. Imaging of combined hepatocellular-cholangiocarcinoma in cirrhosis and risk of false diagnosis of hepatocellular carcinoma. United European Gastroenterol J,2019,7:69-77.
[8] Sammon J,Fischer S,Menezes R, et al. MRI features of combined hepatocellular- cholangiocarcinoma versus mass forming intrahepatic cholangiocarcinoma. Cancer Imaging,2018,18:8.
[9] Wu C,Yong C,Liew E, et al. Combined Hepatocellular Carcinoma and Cholangiocarcinoma:Diagnosis and Prognosis After Resection or Transplantation. Transplant Proc,2016,48:1100-1104.
[10] Yang J,Zhang Y,Li J, et al. Contrast-enhanced ultrasound in association with serum biomarkers for differentiating combined hepatocellular-cholangiocarcinoma from hepatocellular carcinoma and intrahepatic cholangiocarcinoma. World J Gastroenterol,2020,26:7325-7337.
[11] Jiang H,Song B,Qin Y, et al. Diagnosis of LI-RADS M lesions on gadoxetate-enhanced MRI: identifying cholangiocarcinoma-containing tumor with serum markers and imaging features. Eur Radiol,2020,
[12] Liu X,Khalvati F,Namdar K, et al. Can machine learning radiomics provide pre-operative differentiation of combined hepatocellular cholangiocarcinoma from hepatocellular carcinoma and cholangiocarcinoma to inform optimal treatment planning? Eur Radiol,2021,31:244-255.
[13] Ishii T,Ito T,Sumiyoshi S, et al. Clinicopathological features and recurrence patterns of combined hepatocellular-cholangiocarcinoma. World J Surg Oncol,2020,18:319.
[14] Zhou Y,Sui C,Zhang X, et al. Influence of cirrhosis on long-term prognosis after surgery in patients with combined hepatocellular-cholangiocarcinoma. BMC Gastroenterol,2017,17:25.
[15] Tao C,Liu W,Jin L, et al. Surgical Treatment of Combined Hepatocellular-Cholangiocarcinoma is as Effective in Elderly Patients as it is in Younger Patients: A Propensity Score Matching Analysis. J Cancer,2018,9:1106-1112.
[16] Jaradat D,Bagias G,Lorf T, et al. Liver transplantation for combined hepatocellular-cholangiocarcinoma: Outcomes and prognostic factors for mortality. A multicenter analysis. Clin Transplant,2021,35:e14094.
[17] Antwi S,Habboush Y,Chase L, et al. Response to Loco-Regional Therapy Predicts Outcomes After Liver Transplantation for Combined Hepatocellular-Cholangiocarcinoma. Ann Hepatol,2018,17:969-979.
[18] Wu D,Shen Z,Zhang Y, et al. Effect of liver transplantation in combined hepatocellular and cholangiocellular carcinoma: a case series. BMC cancer,2015,15:232.
[19] Lee J,Chung G,Yu S, et al. Long-term prognosis of combined hepatocellular and cholangiocarcinoma after curative resection comparison with hepatocellular carcinoma and cholangiocarcinoma. J Clin Gastroenterol,2011,45:69-75.
[20] Badar W,Van Ha T,Zangan S, et al. Yttrium-90 Radioembolization Therapy for Combined Hepatocellular and Cholangiocarcinoma. Gastrointest Tumors,2020,7:144-150.
[21] Chan L,Sze D,Poultsides G, et al. Yttrium-90 Radioembolization for Unresectable Combined Hepatocellular-Cholangiocarcinoma. Cardiovasc Intervent Radiol,2017,40:1383-1391.
[22] Kim J,Yoon H,Ko G, et al. Nonresectable combined hepatocellular carcinoma and cholangiocarcinoma: analysis of the response and prognostic factors after transcatheter arterial chemoembolization. Radiology,2010,255:270-277.
[23] Na S,Choi G,Lee H, et al. The effectiveness of transarterial chemoembolization in recurrent hepatocellular-cholangiocarcinoma after resection. PLoS One,2018,13:e0198138.
[24] Park S,Lee S,Yu E, et al. Combined hepatocellular-cholangiocarcinoma: Gadoxetic acid-enhanced MRI findings correlated with pathologic features and prognosis. J Magn Reson Imaging,2017,46:267-280.
[25] Fowler K,Saad N,Brunt E, et al. Biphenotypic Primary Liver Carcinomas: Assessing Outcomes of Hepatic Directed Therapy. Ann Surg Oncol,2015,22:4130-4137.
[26] Raevskaya O,Appelman H,Razumilava N. A Contemporary Approach to Diagnosis and Treatment of Combined Hepatocellular-Cholangiocarcinoma. Curr Hepatol Rep,2020,19:478-485.
[27] Kim E,Yoo C,Kang H, et al. Clinical outcomes of systemic therapy in patients with unresectable or metastatic combined hepatocellular-cholangiocarcinoma. Liver Int,2021.
[28] Kobayashi S,Terashima T,Shiba S, et al. Multicenter retrospective analysis of systemic chemotherapy for unresectable combined hepatocellular and cholangiocarcinoma. Cancer Sci,2018,109:2549-2557.
[29] Trikalinos N,Zhou A,Doyle M, et al. Systemic Therapy for Combined Hepatocellular-Cholangiocarcinoma: A Single-Institution Experience. J Natl Compr Canc Netw,2018,16:1193-1199.
[30] Rogers J,Bolonesi R,Rashid A, et al. Systemic therapy for unresectable, mixed hepatocellular-cholangiocarcinoma: treatment of a rare malignancy. J Gastrointest Oncol,2017,8:347-351.
[31] Salimon M,Prieux-Klotz C,Tougeron D, et al. Gemcitabine plus platinum-based chemotherapy for first-line treatment of hepatocholangiocarcinoma: an AGEO French multicentre retrospective study. Br J Cancer,2018,118:325-330.
[32] Liu Z,Lian B,Dong Q, et al. Whole-exome mutational and transcriptional landscapes of combined hepatocellular cholangiocarcinoma and intrahepatic cholangiocarcinoma reveal molecular diversity. Biochim Biophys Acta Mol Basis Dis,2018,1864:2360-2368. |
